← Eichor
Study identifier: NCT06675864 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Condition: Progressive Multiple Sclerosis  ·  Sponsor: Novartis Pharmaceuticals

PhasePhase 1/Phase 2
Planned participants28
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals  ·  +41613241111  ·  novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (18)

Novartis Investigative SiteDarlinghurst, New South Wales, AustraliaRecruiting
Novartis Investigative SiteMelbourne, Victoria, AustraliaRecruiting
Novartis Investigative SiteQuébec, Quebec, CanadaRecruiting
Novartis Investigative SiteBron, FranceRecruiting
Novartis Investigative SiteMontpellier, FranceRecruiting
Novartis Investigative SiteNancy, FranceRecruiting
Novartis Investigative SiteRennes, FranceRecruiting
Novartis Investigative SiteEssen, GermanyRecruiting
Novartis Investigative SiteMainz, GermanyRecruiting
Novartis Investigative SiteUlm, GermanyRecruiting
Novartis Investigative SiteGenova, GE, ItalyRecruiting
Novartis Investigative SiteMilan, MI, ItalyRecruiting

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06675864